FDA Issues First Device 'Close-Out' Letter; Experts Weigh In On Details
This article was originally published in The Silver Sheet
Executive Summary
THE FIRST QUALITY-RELATED DEVICE 'CLOSE-OUT' LETTER was sent by FDA to manufacturer Z-Medica on March 1, officially closing out a December 2009 warning letter that cited the firm for four violations of the Quality System Regulation. Z-Medica's close-out letter came surprisingly fast, given initial expectations from CDRH's Office of Compliance that close-outs could take up to a year. How quickly future close-out letters are issued depends on the specific violations and whether a follow-up inspection is needed, said Larry Spears, deputy director of regulatory affairs in the compliance office. Attorneys debate whether Z-Medica deserved the close-out letter and whether the contents were sufficient. Z-Medica explains how it fixed its quality problems and gained resolution with FDA in less than five months
You may also be interested in...
Debate Grows Around Timeliness Of FDA Close-Out Letters; Warning Letters Going Out Faster
Writing a thorough warning letter response just might help a manufacturer receive an FDA close-out letter more quickly. A well-crafted response can help the agency decide whether to close out some warning letters without performing a reinspection. “If we can conduct a paper review of a firm that has revamped its MDR [Medical Device Reporting] processes, and we find those MDR processes acceptable based on the paper review, then we may be able to close out the warning letter,” CDRH Office of Compliance Director Steven Silverman said. Because it can take a long time for FDA to revisit a firm, the close-out process has slowed to a crawl, some experts say. In warning letter news, FDA is pushing letters out the door faster. There were 121 quality-related letters posted on the agency’s website in 2011, an increase of 30 percent over the prior year.
FDA Warning Letters
WARNING LETTERS: Edwards Lifesciences cited for failing to notify FDA after it received six reports of adverse events that resulted in a death or serious injury
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?